Thrombosis associated with angiogenesis inhibitors

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 1, 2009, Pages 115-128

  Elice, Francesca ^a   Rodeghiero, Francesco ^a   Falanga, Anna ^b   Rickles, Frederick R ^c  

^a SAN BORTOLO HOSPITAL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

angiogenesis; anti angiogenic agents; bavacizumab; cancer; lenalidomide; semaxibin; sorafenib; sunitinib; thalidomide; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; OXALIPLATIN; PACLITAXEL; PLACEBO; POMALIDOMIDE; PREDNISONE; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB;

ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLON CANCER; COLON PERFORATION; COLORECTAL CANCER; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; EPISTAXIS; GASTROINTESTINAL STROMAL TUMOR; HEMOPTYSIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUROPATHY; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; THROMBOSIS PREVENTION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS; THROMBOSIS;

EID: 61649127110     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.01.001     Document Type: Review

References (100)

1. Edwards R.L., Klaus M., Matthews E., et al. Heparin abolishes the chemotherapy-induced increases in plasma fibrinopeptide A levels. Am J Med 89 (1990) 25-28
2. Mailloux A., Grenet K., Bruneel A., et al. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol 80 (2001) 442-449
3. Elice F., Jacoub J., Rickles F.R., et al. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 83 (2008) 862-870
4. Falanga A., and Rickles F.R. The pathogenesis of thrombosis in cancer. New Oncol Thromb 1 (2005) 9-16
5. Winn R., and Harlan J. The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost 3 (2005) 1815-1824
6. Nijziel M.R., van Oerle R., Hillen H.F.P., et al. From Trousseau to angiogenesis: the link between the haemostatic system and cancer. Neth J Med 64 (2006) 403-410
7. Shoji M., Hancock W.W., Abe K., et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 52 (1998) 399-411
8. Zhang Y., Deng Y., Luther T., et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94 (1994) 1320-1327
9. Abe K., Shoji M., Chen J., et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 96 (1999) 8663-8668
10. Goodnough L.T., Saito H., Manni A., et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five day chemotherapy regimen. A study of 159 patients. Cancer 54 (1984) 1264-1268
11. Levine M.N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318 (1988) 404-407
12. Rickles F.R., and Levine M.N. Epidemiology of thrombosis in cancer. Acta Haematol 106 Suppl. (2001) 6-12
13. Blom J.W., Doggen C.J., Osanto S., et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
14. Prandoni P., Lensing A.W., Buller H.R., et al. Deep-vein thrombosis and incidence of subsequent symptomatic cancer. N Engl J Med 327 (1992) 1128-1133
15. Esmon C. The interactions between inflammation and coagulation. Br J Haematol 131 (2005) 417-430
16. Ay C., Simanek R., Vormittag R., et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112 (2008) 2703-2708
17. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98 (2001) 492-494
18. Tosi P., Zamagni E., Cellini C., et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 87 (2002) 408-414
19. Kumar S., Gertz M.A., Dispenzieri A., et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78 (2003) 34-39
20. Rajkumar S.V., Gertz M.A., Lacy M.Q., et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 17 (2003) 775-779
21. Palumbo A., Bertola A., Falco P., et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 5 (2004) 318-324
22. Dimopoulos M.A., Zervas K., Kouvatseas G., et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12 (2001) 991-995
23. Rajkumar S.V., Hayman S., Gertz M.A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20 (2002) 4319-4323
24. Cavo M., Zamagni E., Cellini C., et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100 (2002) 2272-2273
25. Zangari M., Siegel E., Barlogie B., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100 (2002) 1168-1171
26. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004) 715-721
27. Oakervee H., Brownell A., Cervi P., et al. A study of the safety and efficacy of thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) in the treatment of younger patients with multiple myeloma: a UK Myeloma Forum Pilot Study. Br J Haematol 117 Suppl. 1 (2002) 65
28. Palumbo A., Bringhen S., Caravita T., et al., Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 367 (2006) 825-831
29. Zangari M., Anaissie E., Barlogie B., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
30. Elice F., Fink L., Tricot G., et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134 (2006) 399-405
31. Raza A., Reeves J.A., Feldman E.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111 (2008) 86-93
32. Dimopoulos M., Spencer A., Attal M., et al., Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
33. Zonder J.A., Barlogie B., Durie B.G., et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108 (2006) 403
34. Richardson P.G., Blood E., Mitsiades C.S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 (2006) 3458-3464
35. Niesvizky R., Martinez-Banos D.M., Gelbshtein U.Y., et al. Prophylactic low-dose aspirin is effective as antithrombotic therapy in patients receiving combination thalidomide or lenalidomide. ASH Annual Meeting Abstracts. Blood 106 (2005) 3454 (abstract)
36. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
37. Palumbo A., Falco P., Corradini P., et al., GIMEMA-Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 25 (2007) 4459-4465
38. Baz R., Walker E., Karam M., et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17 (2006) 1766-1771
39. Klein U., Kosely F., Hillengaß J., et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 88 1 (2009) 67-71
40. Schey S.A., Fields P., Bartlett J.B., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapse or refractory multiple myeloma. J Clin Oncol 22 (2004) 3269-3276
41. Streetly M.J., Gyertson K., Daniel Y., et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 141 (2008) 41-51
42. Zangari M., Saghafifar F., Anaissie E., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13 (2002) 187-192
43. Minnema M.C., Fijnheer R., De Groot P.G., et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 1 (2003) 445-449
44. Streetly M., Hunt B.J., Parmar K., et al. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 74 (2005) 293-296
45. Weber D., Ginsberg C., Walker P., et al. Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone(TD). Blood 100 (2002) 787 (abstract)
46. Corso A., Lorenzi A., Terulla V., et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 83 (2004) 588-591
47. Desai A.A., Vogelzang N.J., Rini B.I., et al. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95 (2002) 1629-1636
48. Kuenen B.C. Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb 33 Suppl. 1 (2003) 13-14
49. Kaushal V., Kaushal G.P., Melkaveri S.N., et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2 (2004) 327-334
50. Steurer M., Sudmeier I., Stauder R., et al. Thromboembolic events in patients with myelodysplasia syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 121 (2003) 101-103
51. Galli M., Elice F., Crippa C., et al. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 89 (2004) 1141-1142
52. Menon S.P., Rajkumar S.V., Lacy M., et al. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112 (2008) 1522-1528
53. Kabbinavar F., Hurwitz H.I., and Fehrenbacher L. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
54. Hurwitz H., Fehrenbacher L., and Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
55. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
56. Kabbinavar F.F., Hambleton J., and Mass R.D. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712
57. Shah M.A., Ilson D., and Kelsen D.P. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23 (2005) 2574-2576
58. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
59. Cohen M.H., Gootenberg J., Keegan P., et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12 (2007) 713-718
60. Giantonio B.J., Catalano P.J., Meropol N.J., et al., Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007) 1539-1544
61. Dvorak H.F., Rickles F.R., et al. Malignancy and hemostasis. In: Colman R.W., Hirsh J., and Marder V.J. (Eds). Hemostasis and thrombosis: basic principles and clinical practice. 5th edn. (2006), Lippincott-Raven, Philadelphia 851-873
62. Kubo H., Fujiwara T., Jussila L., et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96 (2000) 546-553
63. Yang R., Thomas G., Bunting S., et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performances. J Cardiovasc Pharmacol 27 (1996) 838-844
64. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
65. Yang J.C., Haworth L., Sherry R.M., et al. Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
66. Kuenen B.C., Tabernero J., and Baselga J. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9 (2003) 1648-1655
67. Heymach J.V., Desai J., Manola J., et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10 (2004) 5732-5740
68. Kuenen B.C., Rosen L., Smit E.F., et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20 (2002) 1657-1667
69. Kuenen B.C., Levi M., Meijers J.C., et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 22 (2002) 1500-1505
70. Kuenen B.C., Levi N., Meijers J.C.M., et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 21 (2003) 2192-2198
71. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
72. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
73. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
74. Saltz L.B., Rosen L.S., Marshall J.L., et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25 (2007) 4793-4799
75. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26 (2008) 650-656
76. Moore M., Hirte H.W., Siu L., et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16 (2005) 1688-1694
77. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
78. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
79. Escudier B., Eisen T., Stadler W.M., et al., TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
80. Richly H., Henning B.F., Kupsch P., et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17 (2006) 866-873
81. Siu L.L., Awada A., Takimoto C.H., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12 (2006) 144-151
82. Mross K., Drevs J., Müller M., et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41 (2005) 1291-1299
83. Thomas A.L., Morgan B., Horsfield M.A., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23 (2005) 4162-4171
84. Joensuu H., De Braud F., Coco P., et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 19 (2008) 173-177
85. Scott E.N., Meinhardt G., Jacques C., et al. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Exp Opin Investig Drugs 16 (2007) 367-379
86. Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5 (2005) 24-26
87. Behrendt C.E., and Ruiz R.B. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 90 (2003) 734-737
88. Bissett D., O'Byrne K.J., von Pawel J., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23 (2005) 842-849
89. Heath E.I., Burtness B.A., Kleinberg L., et al. Phase II, parallel-design study of preoperative combined modalità therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs 24 (2006) 135-140
90. Herbst R.S., Hammond L.A., Carbone D.P., et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 9 (2003) 4108-4115
91. Herbst R.S., Hess K.R., Tran H.T., et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20 (2002) 3792-3803
92. Beerepoot L.V., Radema S.A., Witteveen E.O., et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24 (2006) 1491-1498
93. Lyman G.H., Khorana A.A., Falanga A., et al., American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 (2007) 5490-5505
94. Geerts W.H., Bergqvist D., Pineo G.F., et al., American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 Suppl. (2008) 381S-453S
95. Minnema M.C., Breitkreutz I., Auwerda J.J., et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18 (2004) 2044-2046
96. Cavo M., Zamagni E., Tosi P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89 (2004) 826-831
97. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80 (2005) 1568-1574
98. Salimichokami M. Combining angiogenesis inhibitors with cytotoxic chemotherapy enhances PSA response in hormone refractory prostate cancer (HRPC), a randomized study of weekly docetaxel alone or in combination with thalidomide. Proc Am Soc Clin Oncol 22 (2003) 429 (Abstract 1725)
99. Hambleton J., Skillings J., Kabbinavar F., et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). ASCO Annual Meeting Proceedings. J Clin Oncol 23 Suppl. (2005) 3554
100. Hambleton J., Novotny W.F., Hurwitz H., et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 22 Suppl. (2004) 3528